About: Enhanced Induction of SARS-CoV Nucleocapsid Protein-Specific Immune Response Using DNA Vaccination followed by Adenovirus Boosting in BALB/c Mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Enhanced Induction of SARS-CoV Nucleocapsid Protein-Specific Immune Response Using DNA Vaccination followed by Adenovirus Boosting in BALB/c Mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Enhanced Induction of SARS-CoV Nucleocapsid Protein-Specific Immune Response Using DNA Vaccination followed by Adenovirus Boosting in BALB/c Mice
Creator	Chunling, Ma Hua, Sun Jian, Qin Jian, Xu Kun, Yao Minsheng, Zhu
Source	Medline; PMC
abstract	OBJECTIVE: To investigate immunogenicity in the induction of humoral and cellular immune responses to genetic vaccines of the recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV)-N gene expressing the same protein plasmid, pcDNA3.1-N, and replication-defective adenoviral vector, rAd-N, in a pcDNA3.1-N prime-rAd-N boost regimen and the reverse sequence in a rAd-N prime-pcDNA3.1-N boost regimen. METHOD: After the mice had been immunized intramuscularly and/or intraperitoneally with pcDNA3.1-N and rAd-N in prime-triple boost immunization, humoral and cellular immune responses were detected. RESULTS: After detection, different levels of anti-N humoral and cellular responses are shown compared to controls. The humoral immune response was induced more effectively by the DNA priming and recombinant adenovirus boosting regimen and the reverse sequence of heterogeneous combinations. There is a significant difference between heterogeneous and homologous vaccinations. However, the cytotoxic T lymphocyte (CTL) response was not significantly altered by the different prime-boost immunizations or the recombinant adenovirus of pcDNA3.1-N prime-rAd-N boost regimen alone, but lymphoproliferation and interferon-γ (IFN-γ) secretion were all enhanced by heterologous combination immunizations compared to homologous combinations. For the reverse sequence immunization regimen, lymphoproliferation, IFN-γ and CTL responses were all significantly weaker compared with pcDNA3.1-N prime-rAd-N boost regimen. CONCLUSION: Taken together, of all the combinations, the prime-triple boost immunization of pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N/rAd-N can effectively induce SARS-CoV-N-specific and strong humoral and cellular immune responses in mice. The present results suggest that DNA immunization followed by recombinant adenovirus boosting could be used as a potential SARS-CoV vaccine in the induction of an enhanced humoral and cellular immune response.
has issue date	2006-08-16(xsd:dateTime)
bibo:doi	10.1159/000094247
bibo:pmid	16809936
has license	no-cc
sha1sum (hex)	92df84431c14b4d2e57d36ac437d52951b282156
schema:url	https://doi.org/10.1159/000094247
resource representing a document's title	Enhanced Induction of SARS-CoV Nucleocapsid Protein-Specific Immune Response Using DNA Vaccination followed by Adenovirus Boosting in BALB/c Mice
has PubMed Central identifier	PMC7179534
has PubMed identifier	16809936
schema:publication	Intervirology
resource representing a document's body	covid:92df84431c14b4d2e57d36ac437d52951b282156#body_text
is schema:about of	named entity 'humoral' named entity 'combinations' named entity 'heterologous' named entity 'SARS-CoV' named entity 'Fax' named entity 'karger' named entity 'STRONG' named entity 'REVERSE' named entity 'RESPONSES' named entity 'HOMOLOGOUS' named entity 'USED' named entity 'COMBINATIONS' named entity 'COMPARED' named entity 'combinations' named entity 'sequence' named entity 'enhanced' named entity 'enhanced' named entity 'interferon' named entity 'CTL' named entity 'DNA' named entity 'cellular immune response' named entity 'vaccine' named entity 'immunizations' named entity 'CTL' named entity 'recombinant' named entity 'immunization' named entity 'adenovirus' named entity 'Promega' named entity 'mice' named entity 'penicillin' named entity 'SARS-CoV' named entity 'experimental groups' named entity 'adenovirus' named entity 'nucleocapsid' named entity '0.01' named entity 'serum' named entity 'CTL' named entity 'protein' named entity 'virus' named entity 'coronaviruses' named entity 'humoral' named entity 'PBS' named entity 'genetic immunization' named entity 'virus' named entity 'antibody' named entity 'immunization' named entity 'experimental groups' named entity 'SARS-CoV' named entity 'plasmid' named entity 'SARS-CoV' named entity 'specific immune response' named entity 'primary antibodies' named entity 'Beijing' named entity 'cell clones' named entity 'simian immunodeficiency virus' named entity 'protein' named entity 'PHA' named entity 'virus' named entity 'injected intramuscularly' named entity 'nucleocapsid' named entity 'SARS virus' named entity 'wavelength' named entity 'statistically significant' named entity 'China' named entity 'nucleocapsid' named entity 'Splenocytes' named entity 'Grand Island' named entity 'nucleocapsid' named entity 'immunization' named entity 'IFN' named entity 'vaccine' named entity 'dendritic cells' named entity 'virus' named entity 'nucleocapsid' named entity 'coronaviruses' named entity 'antigens'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software